Teleflex price target lowered to $191 from $275 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Teleflex (TFX) to $191 from $275 and keeps an Overweight rating on the shares. The investment thesis has “fundamentally changed” as in addition to the announced spin and Biotronik vascular intervention deal, the Q4 report was “lackluster” and headwinds impacting the 2025 outlook are “significant,” the analyst tells investors. However, noting that there was “a lot for investors to digest on Thursday,” and that these moves largely render 2025 a transition year with lower earnings power and to some extent impacts and risks 2026, the firm is still bullish on Teleflex following the reset of expectations, the analyst added.